Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy

Identifieur interne : 001E57 ( Main/Exploration ); précédent : 001E56; suivant : 001E58

Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy

Auteurs : C. J. Corrigan ; R. J. Shiner [Royaume-Uni] ; B. H. Shakur [Royaume-Uni] ; P. W. Ind [Royaume-Uni]

Source :

RBID : ISTEX:CEADC4F7ED0E4411128BB58CFFE198D29F8A7087

English descriptors

Abstract

Background Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance. Objective To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction. Methods Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified a priori as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by 50% or <50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks. Results MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (P<0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation. Conclusion MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.

Url:
DOI: 10.1111/j.1365-2222.2005.02253.x


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title>
<author>
<name sortKey="Corrigan, C J" sort="Corrigan, C J" uniqKey="Corrigan C" first="C. J." last="Corrigan">C. J. Corrigan</name>
</author>
<author>
<name sortKey="Shiner, R J" sort="Shiner, R J" uniqKey="Shiner R" first="R. J." last="Shiner">R. J. Shiner</name>
</author>
<author>
<name sortKey="Shakur, B H" sort="Shakur, B H" uniqKey="Shakur B" first="B. H." last="Shakur">B. H. Shakur</name>
</author>
<author>
<name sortKey="Ind, P W" sort="Ind, P W" uniqKey="Ind P" first="P. W." last="Ind">P. W. Ind</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CEADC4F7ED0E4411128BB58CFFE198D29F8A7087</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1111/j.1365-2222.2005.02253.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-KJ4KSHV8-W/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001792</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001792</idno>
<idno type="wicri:Area/Istex/Curation">001792</idno>
<idno type="wicri:Area/Istex/Checkpoint">000D07</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D07</idno>
<idno type="wicri:doubleKey">0954-7894:2005:Corrigan C:methotrexate:therapy:of</idno>
<idno type="wicri:Area/Main/Merge">001E71</idno>
<idno type="wicri:Area/Main/Curation">001E57</idno>
<idno type="wicri:Area/Main/Exploration">001E57</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy</title>
<author>
<name sortKey="Corrigan, C J" sort="Corrigan, C J" uniqKey="Corrigan C" first="C. J." last="Corrigan">C. J. Corrigan</name>
<affiliation>
<wicri:noCountry code="subField">Thomas'</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Shiner, R J" sort="Shiner, R J" uniqKey="Shiner R" first="R. J." last="Shiner">R. J. Shiner</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Imperial College Schools of Medicine, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Shakur, B H" sort="Shakur, B H" uniqKey="Shakur B" first="B. H." last="Shakur">B. H. Shakur</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Imperial College Schools of Medicine, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ind, P W" sort="Ind, P W" uniqKey="Ind P" first="P. W." last="Ind">P. W. Ind</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Imperial College Schools of Medicine, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Clinical & Experimental Allergy</title>
<title level="j" type="alt">CLINICAL EXPERIMENTAL ALLERGY</title>
<idno type="ISSN">0954-7894</idno>
<idno type="eISSN">1365-2222</idno>
<imprint>
<biblScope unit="vol">35</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="579">579</biblScope>
<biblScope unit="page" to="584">584</biblScope>
<biblScope unit="page-count">6</biblScope>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-05">2005-05</date>
</imprint>
<idno type="ISSN">0954-7894</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0954-7894</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Allergy</term>
<term>Allergy clin immunol</term>
<term>Asthma</term>
<term>Asthmatic</term>
<term>Asthmatic patients</term>
<term>Baseline</term>
<term>Baseline prednisolone dosages</term>
<term>Blackwell publishing</term>
<term>Clin</term>
<term>Dosage</term>
<term>Experimental allergy</term>
<term>Fev1</term>
<term>Immunoglobulin</term>
<term>Immunol</term>
<term>Individual patients</term>
<term>Leucocyte</term>
<term>Lung function</term>
<term>Methotrexate</term>
<term>Methotrexate therapy</term>
<term>Oral asthmatics</term>
<term>Oral prednisolone</term>
<term>Parametric anova</term>
<term>Percentage changes</term>
<term>Percentage reductions</term>
<term>Prednisolone</term>
<term>Prednisolone dosage</term>
<term>Prednisolone dosages</term>
<term>Responder</term>
<term>Rheumatoid arthritis</term>
<term>Serum concentrations</term>
<term>Severe asthmatics</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Background Concomitant methotrexate (MTX) therapy of oral corticosteroid (CS)–dependent asthmatics has been shown to spare CS therapy, but the mechanism is unknown. In a previous report, we showed that MTX increases T cell inhibition by CS. In this report we focus on effects of MTX on immunoglobulin concentrations and their possible clinical relevance. Objective To monitor changes in circulating leucocytes and Ig in a group of these patients during MTX therapy, and to relate these changes to clinical ‘response’ as defined by oral CS reduction. Methods Sixteen severe asthmatics dependent on oral prednisolone 15 (7.5–25) mg/day in addition to high dose inhaled CS were treated with MTX 15 mg intramuscularly, weekly for 28 weeks. Prednisolone dosages were maintained constant for 12 weeks then reduced systematically over the next 16 weeks provided that asthma control did not deteriorate. Patients were classified a priori as ‘responders’ or ‘non‐responders’ to MTX (reduction of initial oral prednisolone requirement by 50% or <50%, respectively). Patients were followed‐up for a further 12 weeks after MTX withdrawal. Serum Ig and differential blood leucocyte counts were measured at baseline, 12, 28 and 40 weeks. Results MTX therapy allowed significant, but individually variable, reductions in oral prednisolone dosages (P<0.00001) without alteration of lung function or symptoms. This was associated with significant reductions in mean serum concentrations of Ig of all classes, which reversed following MTX withdrawal. Reductions in IgE and IgG were significantly greater in the MTX ‘responders’ as compared with ‘non‐responders’, and changes in IgE, IgG and IgM correlated with changes in prednisolone requirements. Differential blood leucocyte counts showed no significant variation. Conclusion MTX therapy reduced oral CS requirements in these severe asthmatics to a degree which correlated with reduced circulating Ig but not lymphopaenia, suggesting a possible cause and effect relationship. These reductions might also contribute to the documented incidence of opportunistic infection in these circumstances.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
<region>
<li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement>
<li>Londres</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Corrigan, C J" sort="Corrigan, C J" uniqKey="Corrigan C" first="C. J." last="Corrigan">C. J. Corrigan</name>
</noCountry>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Shiner, R J" sort="Shiner, R J" uniqKey="Shiner R" first="R. J." last="Shiner">R. J. Shiner</name>
</region>
<name sortKey="Ind, P W" sort="Ind, P W" uniqKey="Ind P" first="P. W." last="Ind">P. W. Ind</name>
<name sortKey="Shakur, B H" sort="Shakur, B H" uniqKey="Shakur B" first="B. H." last="Shakur">B. H. Shakur</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E57 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E57 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:CEADC4F7ED0E4411128BB58CFFE198D29F8A7087
   |texte=   Methotrexate therapy of oral corticosteroid‐dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021